| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0eb300f8bb645d8c16e83b2fd3abb9cd |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 |
| filingDate |
1992-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aaf99b2d4e54439c6cffb10375836161
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2be29ed217ce90794cf22b3ac93468d8 |
| publicationDate |
1993-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9308808-A2 |
| titleOfInvention |
Use of gangliosides in the preparation of pharmaceuticals which can improve the progonosis of disorders due to psychotropics and drugs abuse |
| abstract |
The following description sets forth a new application of monosialoganglioside GM1, of its inner ester AGF2, and of their pharmacologically acceptable salts in the preparation of pharmaceuticals active in the prevention of behavioural and cognitive disorders following cocaine and related psychostimulants abuse. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0812191-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0812191-A1 |
| priorityDate |
1991-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |